Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameGiant Biogene
Stock Code02367
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是中國基於生物活性成分的專業皮膚護理產品行業的領軍者,設計、開發和生產以重組膠原蛋白為關鍵生物活性成分的專業皮膚護理產品,亦開發和生產基於稀有人參皂苷技術的保健食品。
Listing Date2022-11-04
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國陝西省西安市長安區上林苑七路1855號
Business Address (Hong Kong)香港九龍觀塘道348號宏利廣場5樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.xajuzi.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 24.30 / shares
Offer Price RangeFinal offer price only, no range
Lot Size200 shares
Entry ThresholdHK$ 4,860
Par ValueTo be extracted
Offer Period2022-10-25 to 2022-10-28
Global Offering Shares22,608,800 shares
HK Public Offer Shares (Initial)2,261,200 shares (10.0%)
Public Offer Lots (Initial)11,306lots (Pool A5,653lots,Pool B5,653lots)
International Placing Shares (Initial)20,347,600 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO991,608,800 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 549,393,840

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 200 HK$ 4,860
2 lots 400 HK$ 9,720
3 lots 600 HK$ 14,580
4 lots 800 HK$ 19,440
5 lots 1,000 HK$ 24,300
6 lots 1,200 HK$ 29,160
7 lots 1,400 HK$ 34,020
8 lots 1,600 HK$ 38,880
9 lots 1,800 HK$ 43,740
10 lots 2,000 HK$ 48,600
15 lots 3,000 HK$ 72,900
20 lots 4,000 HK$ 97,200
25 lots 5,000 HK$ 121,500
30 lots 6,000 HK$ 145,800
35 lots 7,000 HK$ 170,100
40 lots 8,000 HK$ 194,400
45 lots 9,000 HK$ 218,700
50 lots 10,000 HK$ 243,000
75 lots 15,000 HK$ 364,500
100 lots 20,000 HK$ 486,000
125 lots 25,000 HK$ 607,500
150 lots 30,000 HK$ 729,000
175 lots 35,000 HK$ 850,500
200 lots 40,000 HK$ 972,000
225 lots 45,000 HK$ 1,093,500
250 lots 50,000 HK$ 1,215,000
300 lots 60,000 HK$ 1,458,000
350 lots 70,000 HK$ 1,701,000
450 lots 90,000 HK$ 2,187,000
500 lots 100,000 HK$ 2,430,000

Stock Connect Inclusion Analysis

Avg Daily HK Mkt Cap HK$ 28.64B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)HK$ 24,096,093,840
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status盈利約人民幣828.1百萬元
Period-End Cash Balance人民幣71.03億元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201920202021
Revenue 956,7021,190,4791,552,486
Cost of sales -159,990-183,410-198,149
Gross profit 796,7121,007,0691,354,337
Other income and gains, net 31,16621,38633,155
Selling and distribution expenses -93,788-158,422-346,211
Administrative expenses -28,845-32,992-72,274
Profit before tax 676,996973,242972,917
Income tax expense -101,816-146,757-144,785
Profit for the year 575,180826,485828,132
Profit attributable to owners 552,260826,450828,132
Balance Sheet
Item 201920202021
Cash and cash equivalents 72,323367,8057,103,000
Trade and bills receivables 17,26054,52365,639
Inventories 50,86364,65689,394
Total current assets 1,458,2552,284,0987,441,322
Total current liabilities 626,0542,173,8906,843,042
Total equity 1,151,449458,0031,016,811
Equity attributable to owners 1,147,698458,0031,016,811
Cash Flow Statement
Item 2019202020212022-05
Net cash from operating activities 656,457834,124692,401
Net cash from investing activities -589,846-521,1191,563,266
Net cash from financing activities -2,164-17,5234,475,544
Net increase in cash 64,447295,4826,731,211
Depreciation of PP&E 16,13518,78820,1119,327
Depreciation of right-of-use assets 673867868830
Amortisation of intangible assets 1,0741,1971,314586
Purchase of PP&E -85,473-75,506-74,999-33,097
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 26.7
First Day OpenHK$ 26.0
First Day Change9.88%
First Day Volume7243000.0
First Day Turnover202303000.0
Use of Proceeds
1、約11%的所得款項凈額(即54.5百萬港元)用于研發投資以通過招聘擴大我們的研發團隊、擴展我們的研發設施及進行測試和驗證研究; 2、約28%的所得款項凈額(即138.8百萬港元)用于擴展與我們的產品組合及生物活性成分有關的生產能力; 3、約46%的所得款項凈額(即228.1百萬港元),用于增強我們的全渠道銷售及經銷網絡,并開展以科學和知識為導向的營銷活動以提高我們的品牌知名度; 4、約5%的所得款項凈額(即24.8百萬港元)用于提升我們運營及信息系統; 5、約10%的所得款項凈額(即49.6百萬港元)用作營運資金及一般公司用途。

Underwriting Syndicate

Joint Sponsors (2)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Overall Coordinators (2)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Joint Bookrunners (3)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Joint Lead Managers (6)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 广发证券(香港)经纪有限公司 CE AOB364 富途证券国际(香港)有限公司 CE AZT137 SILVERBRICKS SECURITIES COMPANY LIMITED CE BLN458

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman嚴建亞—
Company Secretary嚴鈺博、姚淑嫻—
No director data available.

Major Shareholders

Major Shareholders & Holdings范博士通過Juzi Holding、Healing Holding及GBEBT Holding合共持有約60.61%投票權;嚴建亞先生為范博士配偶,亦構成控股股東。
About this page

This page shows Giant Biogene (02367) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect